ID   KAT6A_HUMAN             Reviewed;        2004 AA.
AC   Q92794; Q76L81;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   10-MAY-2017, entry version 186.
DE   RecName: Full=Histone acetyltransferase KAT6A;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:11313971, ECO:0000269|PubMed:11742995};
DE   AltName: Full=MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3;
DE            Short=MYST-3;
DE   AltName: Full=Monocytic leukemia zinc finger protein;
DE   AltName: Full=Runt-related transcription factor-binding protein 2;
DE   AltName: Full=Zinc finger protein 220;
GN   Name=KAT6A; Synonyms=MOZ, MYST3, RUNXBP2, ZNF220;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION WITH CREBBP.
RX   PubMed=8782817; DOI=10.1038/ng0996-33;
RA   Borrow J., Stanton V.P. Jr., Andresen J.M., Becher R., Behm F.G.,
RA   Chaganti R.S.K., Civin C.I., Disteche C., Dube I., Frischauf A.M.,
RA   Horsman D., Mitelman F., Volinia S., Watmore A.E., Housman D.E.;
RT   "The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a
RT   putative acetyltransferase to the CREB-binding protein.";
RL   Nat. Genet. 14:33-41(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-813, AND CHROMOSOMAL TRANSLOCATION
RP   WITH ASXL2.
RC   TISSUE=Bone marrow;
RA   Hosoda F., Kitabayashi I., Kakazu N., Fukushima M., Aikawa Y., Abe T.,
RA   Hibi S., Yagi T., Ohki M.;
RT   "MOZ is fused to a novel Polycomb group gene in a therapy-related
RT   myelodysplastic syndrome with t(2;8)(p23;p11.2).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1089-1117, AND CHROMOSOMAL TRANSLOCATION
RP   WITH NCOA2.
RX   PubMed=9558366;
RA   Carapeti M., Aguiar R.C.T., Goldman J.M., Cross N.C.P.;
RT   "A novel fusion between MOZ and the nuclear receptor coactivator TIF2
RT   in acute myeloid leukemia.";
RL   Blood 91:3127-3133(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1111-1128, AND CHROMOSOMAL TRANSLOCATION
RP   WITH EP300.
RX   PubMed=10824998;
RX   DOI=10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2;
RA   Chaffanet M., Gressin L., Preudhomme C., Soenen-Cornu V., Birnbaum D.,
RA   Pebusque M.-J.;
RT   "MOZ is fused to p300 in an acute monocytic leukemia with t(8;22).";
RL   Genes Chromosomes Cancer 28:138-144(2000).
RN   [6]
RP   INTERACTION WITH RUNX1, SUBCELLULAR LOCATION, CATALYTIC ACTIVITY,
RP   ACETYLATION, CHROMOSOMAL TRANSLOCATION WITH CREBBP, AND FUNCTION.
RX   PubMed=11742995; DOI=10.1093/emboj/20.24.7184;
RA   Kitabayashi I., Aikawa Y., Nguyen L.A., Yokoyama A., Ohki M.;
RT   "Activation of AML1-mediated transcription by MOZ and inhibition by
RT   the MOZ-CBP fusion protein.";
RL   EMBO J. 20:7184-7196(2001).
RN   [7]
RP   CATALYTIC ACTIVITY, AND DOMAIN.
RX   PubMed=11313971; DOI=10.1038/sj.onc.1204114;
RA   Champagne N., Pelletier N., Yang X.-J.;
RT   "The monocytic leukemia zinc finger protein MOZ is a histone
RT   acetyltransferase.";
RL   Oncogene 20:404-409(2001).
RN   [8]
RP   INTERACTION WITH RUNX2, AND FUNCTION.
RX   PubMed=11965546; DOI=10.1038/sj.onc.1205367;
RA   Pelletier N., Champagne N., Stifani S., Yang X.-J.;
RT   "MOZ and MORF histone acetyltransferases interact with the Runt-domain
RT   transcription factor Runx2.";
RL   Oncogene 21:2729-2740(2002).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH NCOA2, AND MUTAGENESIS OF CYS-543 AND
RP   GLY-657.
RX   PubMed=12676584; DOI=10.1016/S1535-6108(03)00051-5;
RA   Deguchi K., Ayton P.M., Carapeti M., Kutok J.L., Snyder C.S.,
RA   Williams I.R., Cross N.C.P., Glass C.K., Cleary M.L., Gilliland D.G.;
RT   "MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome
RT   binding motif and TIF2-mediated recruitment of CBP.";
RL   Cancer Cell 3:259-271(2003).
RN   [10]
RP   FUNCTION.
RX   PubMed=12771199; DOI=10.1093/nar/gkg401;
RA   Bristow C.A.P., Shore P.;
RT   "Transcriptional regulation of the human MIP-1alpha promoter by RUNX1
RT   and MOZ.";
RL   Nucleic Acids Res. 31:2735-2744(2003).
RN   [11]
RP   SUBCELLULAR LOCATION, AND CHROMOSOMAL TRANSLOCATION WITH NCOA2.
RX   PubMed=15657427; DOI=10.1128/MCB.25.3.988-1002.2005;
RA   Kindle K.B., Troke P.J.F., Collins H.M., Matsuda S., Bossi D.,
RA   Bellodi C., Kalkhoven E., Salomoni P., Pelicci P.G., Minucci S.,
RA   Heery D.M.;
RT   "MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by
RT   impairment of CBP function.";
RL   Mol. Cell. Biol. 25:988-1002(2005).
RN   [12]
RP   FUNCTION, AND IDENTIFICATION IN THE MOZ/MORF COMPLEX.
RX   PubMed=16387653; DOI=10.1016/j.molcel.2005.12.007;
RA   Doyon Y., Cayrou C., Ullah M., Landry A.-J., Cote V., Selleck W.,
RA   Lane W.S., Tan S., Yang X.-J., Cote J.;
RT   "ING tumor suppressor proteins are critical regulators of chromatin
RT   acetylation required for genome expression and perpetuation.";
RL   Mol. Cell 21:51-64(2006).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [14]
RP   IDENTIFICATION IN THE MOZ/MORF COMPLEX, INTERACTION WITH BRPF1, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=18794358; DOI=10.1128/MCB.01297-08;
RA   Ullah M., Pelletier N., Xiao L., Zhao S.P., Wang K., Degerny C.,
RA   Tahmasebi S., Cayrou C., Doyon Y., Goh S.-L., Champagne N., Cote J.,
RA   Yang X.-J.;
RT   "Molecular architecture of quartet MOZ/MORF histone acetyltransferase
RT   complexes.";
RL   Mol. Cell. Biol. 28:6828-6843(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1113, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-350; LYS-355 AND LYS-1007,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-473 AND SER-1113, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-420; SER-473; SER-812;
RP   SER-941; SER-954; SER-974; SER-1089; SER-1090 AND SER-1113, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   FUNCTION, INTERACTION WITH PML AND TP53, AND PHOSPHORYLATION AT
RP   THR-369.
RX   PubMed=23431171; DOI=10.1073/pnas.1300490110;
RA   Rokudai S., Laptenko O., Arnal S.M., Taya Y., Kitabayashi I.,
RA   Prives C.;
RT   "MOZ increases p53 acetylation and premature senescence through its
RT   complex formation with PML.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:3895-3900(2013).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [22]
RP   INVOLVEMENT IN MRD32.
RX   PubMed=25728775; DOI=10.1016/j.ajhg.2015.01.017;
RG   UCLA Clinical Genomics Center;
RA   Arboleda V.A., Lee H., Dorrani N., Zadeh N., Willis M., Macmurdo C.F.,
RA   Manning M.A., Kwan A., Hudgins L., Barthelemy F., Miceli M.C.,
RA   Quintero-Rivera F., Kantarci S., Strom S.P., Deignan J.L., Grody W.W.,
RA   Vilain E., Nelson S.F.;
RT   "De novo nonsense mutations in KAT6A, a lysine acetyl-transferase
RT   gene, cause a syndrome including microcephaly and global developmental
RT   delay.";
RL   Am. J. Hum. Genet. 96:498-506(2015).
RN   [23]
RP   INVOLVEMENT IN MRD32.
RX   PubMed=25728777; DOI=10.1016/j.ajhg.2015.01.016;
RA   Tham E., Lindstrand A., Santani A., Malmgren H., Nesbitt A.,
RA   Dubbs H.A., Zackai E.H., Parker M.J., Millan F., Rosenbaum K.,
RA   Wilson G.N., Nordgren A.;
RT   "Dominant mutations in KAT6A cause intellectual disability with
RT   recognizable syndromic features.";
RL   Am. J. Hum. Genet. 96:507-513(2015).
RN   [24]
RP   STRUCTURE BY NMR OF 531-563.
RA   Kwan A.H.Y., Gell D.A., Liew C.K., Mackay J.P.;
RT   "Solution structure of a CCCCCHC zinc finger from MOZ.";
RL   Submitted (JUN-2002) to the PDB data bank.
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 501-784 IN COMPLEXES WITH
RP   ACETYL-COA; HISTONE H3 AND HISTONE H4 AND ZINC IONS, FUNCTION,
RP   CATALYTIC ACTIVITY, DNA-BINDING, AND MUTAGENESIS OF LYS-545; ILE-727
RP   AND HIS-732.
RX   PubMed=17925393; DOI=10.1074/jbc.M705812200;
RA   Holbert M.A., Sikorski T., Carten J., Snowflack D., Hodawadekar S.,
RA   Marmorstein R.;
RT   "The human monocytic leukemia zinc finger histone acetyltransferase
RT   domain contains DNA-binding activity implicated in chromatin
RT   targeting.";
RL   J. Biol. Chem. 282:36603-36613(2007).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 497-780 IN COMPLEX WITH
RP   ACETYL-COA, AND ACETYLATION AT LYS-604.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of human MYST histone acetyltransferase 3 in
RT   complex with acetylcoenzyme A.";
RL   Submitted (FEB-2009) to the PDB data bank.
CC   -!- FUNCTION: Histone acetyltransferase that acetylates lysine
CC       residues in histone H3 and histone H4 (in vitro). Component of the
CC       MOZ/MORF complex which has a histone H3 acetyltransferase
CC       activity. May act as a transcriptional coactivator for RUNX1 and
CC       RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls
CC       its transcriptional activity via association with PML.
CC       {ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:11965546,
CC       ECO:0000269|PubMed:12771199, ECO:0000269|PubMed:16387653,
CC       ECO:0000269|PubMed:17925393, ECO:0000269|PubMed:23431171}.
CC   -!- CATALYTIC ACTIVITY: Acetyl-CoA + [protein]-L-lysine = CoA +
CC       [protein]-N(6)-acetyl-L-lysine. {ECO:0000269|PubMed:11313971,
CC       ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:17925393}.
CC   -!- SUBUNIT: Component of the MOZ/MORF complex composed at least of
CC       ING5, KAT6A, KAT6B, MEAF6 and one of BRPF1, BRD1/BRPF2 and BRPF3.
CC       Interacts with RUNX1; phosphorylation of RUNX1 enhances the
CC       interaction. Interacts with RUNX2. Interacts with p53/TP53.
CC       Interacts with PML (isoform PML-4) and this interaction positively
CC       regulates its acetylation activity towards p53/TP53.
CC       {ECO:0000269|PubMed:11742995, ECO:0000269|PubMed:11965546,
CC       ECO:0000269|PubMed:16387653, ECO:0000269|PubMed:18794358,
CC       ECO:0000269|PubMed:23431171, ECO:0000269|Ref.26}.
CC   -!- INTERACTION:
CC       Q03164:KMT2A; NbExp=10; IntAct=EBI-948013, EBI-2638616;
CC       P61964:WDR5; NbExp=4; IntAct=EBI-948013, EBI-540834;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Nucleus, nucleolus. Nucleus,
CC       nucleoplasm. Nucleus, PML body. Note=Recruited into PML body after
CC       DNA damage.
CC   -!- DOMAIN: The N-terminus is involved in transcriptional activation
CC       while the C-terminus is involved in transcriptional repression.
CC       {ECO:0000269|PubMed:11313971}.
CC   -!- PTM: Autoacetylation at Lys-604 is required for proper function
CC       (By similarity). Autoacetylated. {ECO:0000250|UniProtKB:Q9H7Z6,
CC       ECO:0000269|Ref.26}.
CC   -!- PTM: Phosphorylation at Thr-369 by PKB/AKT1 inhibits its
CC       interaction with PML and negatively regulates its acetylation
CC       activity towards p53/TP53. {ECO:0000269|PubMed:11742995,
CC       ECO:0000269|PubMed:23431171}.
CC   -!- DISEASE: Note=Chromosomal aberrations involving KAT6A may be a
CC       cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13)
CC       with CREBBP (PubMed:8782817). Translocation t(8;22)(p11;q13) with
CC       EP300 (PubMed:10824998). KAT6A-CREBBP may induce leukemia by
CC       inhibiting RUNX1-mediated transcription (PubMed:11742995).
CC       Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene,
CC       which consists of the N-terminal part of KAT6A and the C-terminal
CC       part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its
CC       function in transcription activation (PubMed:12676584).
CC       {ECO:0000269|PubMed:10824998, ECO:0000269|PubMed:11742995,
CC       ECO:0000269|PubMed:12676584, ECO:0000269|PubMed:8782817}.
CC   -!- DISEASE: Note=A chromosomal aberration involving KAT6A is a cause
CC       of therapy-related myelodysplastic syndrome. Translocation
CC       t(2;8)(p23;p11.2) with ASXL2 generates a KAT6A-ASXL2 fusion
CC       protein. {ECO:0000269|Ref.3}.
CC   -!- DISEASE: Mental retardation, autosomal dominant 32 (MRD32)
CC       [MIM:616268]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRD32 patients
CC       manifest intellectual disability, dysmorphic facial features,
CC       delayed psychomotor development, and lack of speech.
CC       {ECO:0000269|PubMed:25728775, ECO:0000269|PubMed:25728777}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the MYST (SAS/MOZ) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MYST3ID25ch8p11.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U47742; AAC50662.1; -; mRNA.
DR   EMBL; AC090571; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB084281; BAD00088.1; ALT_TERM; mRNA.
DR   CCDS; CCDS6124.1; -.
DR   RefSeq; NP_006757.2; NM_006766.4.
DR   RefSeq; XP_016869352.1; XM_017013863.1.
DR   RefSeq; XP_016869353.1; XM_017013864.1.
DR   UniGene; Hs.491577; -.
DR   PDB; 1M36; NMR; -; A=533-563.
DR   PDB; 2LN0; NMR; -; A=204-313.
DR   PDB; 2OZU; X-ray; 2.30 A; A=497-780.
DR   PDB; 2RC4; X-ray; 3.00 A; A=501-784.
DR   PDB; 3V43; X-ray; 1.47 A; A=204-313.
DR   PDB; 4LJN; X-ray; 3.00 A; A=194-323.
DR   PDB; 4LK9; X-ray; 1.60 A; A=194-323.
DR   PDB; 4LKA; X-ray; 1.61 A; A=194-323.
DR   PDB; 4LLB; X-ray; 2.50 A; A/B=194-323.
DR   PDB; 5B75; X-ray; 1.70 A; A=194-323.
DR   PDB; 5B76; X-ray; 1.65 A; A=194-323.
DR   PDB; 5B77; X-ray; 1.55 A; A=194-323.
DR   PDB; 5B78; X-ray; 1.40 A; A=194-323.
DR   PDBsum; 1M36; -.
DR   PDBsum; 2LN0; -.
DR   PDBsum; 2OZU; -.
DR   PDBsum; 2RC4; -.
DR   PDBsum; 3V43; -.
DR   PDBsum; 4LJN; -.
DR   PDBsum; 4LK9; -.
DR   PDBsum; 4LKA; -.
DR   PDBsum; 4LLB; -.
DR   PDBsum; 5B75; -.
DR   PDBsum; 5B76; -.
DR   PDBsum; 5B77; -.
DR   PDBsum; 5B78; -.
DR   ProteinModelPortal; Q92794; -.
DR   SMR; Q92794; -.
DR   BioGrid; 113703; 42.
DR   IntAct; Q92794; 21.
DR   STRING; 9606.ENSP00000265713; -.
DR   iPTMnet; Q92794; -.
DR   PhosphoSitePlus; Q92794; -.
DR   BioMuta; KAT6A; -.
DR   DMDM; 215274095; -.
DR   EPD; Q92794; -.
DR   MaxQB; Q92794; -.
DR   PaxDb; Q92794; -.
DR   PeptideAtlas; Q92794; -.
DR   PRIDE; Q92794; -.
DR   DNASU; 7994; -.
DR   Ensembl; ENST00000265713; ENSP00000265713; ENSG00000083168.
DR   Ensembl; ENST00000396930; ENSP00000380136; ENSG00000083168.
DR   Ensembl; ENST00000406337; ENSP00000385888; ENSG00000083168.
DR   GeneID; 7994; -.
DR   KEGG; hsa:7994; -.
DR   UCSC; uc003xon.4; human.
DR   CTD; 7994; -.
DR   DisGeNET; 7994; -.
DR   GeneCards; KAT6A; -.
DR   HGNC; HGNC:13013; KAT6A.
DR   HPA; CAB017023; -.
DR   HPA; HPA063266; -.
DR   HPA; HPA065052; -.
DR   MalaCards; KAT6A; -.
DR   MIM; 601408; gene.
DR   MIM; 616268; phenotype.
DR   neXtProt; NX_Q92794; -.
DR   OpenTargets; ENSG00000083168; -.
DR   Orphanet; 370026; Acute myeloid leukemia with t(8;16)(p11;p13) translocation.
DR   PharmGKB; PA37592; -.
DR   eggNOG; KOG2747; Eukaryota.
DR   eggNOG; COG5027; LUCA.
DR   GeneTree; ENSGT00550000074503; -.
DR   HOGENOM; HOG000234365; -.
DR   HOVERGEN; HBG052563; -.
DR   InParanoid; Q92794; -.
DR   KO; K11305; -.
DR   OMA; EGAYQDC; -.
DR   OrthoDB; EOG091G00D2; -.
DR   PhylomeDB; Q92794; -.
DR   TreeFam; TF106483; -.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   SIGNOR; Q92794; -.
DR   ChiTaRS; KAT6A; human.
DR   EvolutionaryTrace; Q92794; -.
DR   GeneWiki; MYST3; -.
DR   GenomeRNAi; 7994; -.
DR   PRO; PR:Q92794; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000083168; -.
DR   CleanEx; HS_MYST3; -.
DR   ExpressionAtlas; Q92794; baseline and differential.
DR   Genevisible; Q92794; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070776; C:MOZ/MORF histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0000786; C:nucleosome; IEA:InterPro.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IDA:UniProtKB.
DR   GO; GO:0016407; F:acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0090398; P:cellular senescence; IMP:UniProtKB.
DR   GO; GO:0006323; P:DNA packaging; TAS:ProtInc.
DR   GO; GO:0016573; P:histone acetylation; IDA:UniProtKB.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:UniProtKB.
DR   GO; GO:0030099; P:myeloid cell differentiation; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006334; P:nucleosome assembly; IEA:InterPro.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0006473; P:protein acetylation; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.10; -; 2.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR002717; HAT_MYST-type.
DR   InterPro; IPR005818; Histone_H1/H5_H15.
DR   InterPro; IPR031280; KAT6A.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10615:SF145; PTHR10615:SF145; 1.
DR   Pfam; PF01853; MOZ_SAS; 1.
DR   Pfam; PF00628; PHD; 1.
DR   SMART; SM00526; H15; 1.
DR   SMART; SM00249; PHD; 2.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   SUPFAM; SSF55729; SSF55729; 1.
DR   SUPFAM; SSF57903; SSF57903; 2.
DR   PROSITE; PS51504; H15; 1.
DR   PROSITE; PS51726; MYST_HAT; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Acyltransferase;
KW   Chromatin regulator; Chromosomal rearrangement; Complete proteome;
KW   Mental retardation; Metal-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat; Repressor;
KW   Transcription; Transcription regulation; Transferase; Zinc;
KW   Zinc-finger.
FT   CHAIN         1   2004       Histone acetyltransferase KAT6A.
FT                                /FTId=PRO_0000051572.
FT   DOMAIN       95    171       H15. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00837}.
FT   DOMAIN      504    778       MYST-type HAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01063}.
FT   ZN_FING     206    265       PHD-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     259    313       PHD-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     537    562       C2HC MYST-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01063}.
FT   REGION        1    144       Required for activation of RUNX1-1.
FT   REGION       52    166       Required for nuclear localization.
FT   REGION      144    664       Interaction with PML.
FT                                {ECO:0000269|PubMed:23431171}.
FT   REGION      312    664       Interaction with RUNX1-1.
FT   REGION      488    778       Catalytic.
FT   REGION      507    810       Mediates interaction with BRPF1, required
FT                                for histone H3 acetyltransferase
FT                                activity. {ECO:0000269|PubMed:18794358}.
FT   REGION      645    649       Acetyl-CoA binding. {ECO:0000269|Ref.26}.
FT   REGION      654    660       Acetyl-CoA binding. {ECO:0000269|Ref.26}.
FT   REGION     1517   1741       Interaction with PML.
FT                                {ECO:0000269|PubMed:23431171}.
FT   REGION     1517   1642       Interaction with RUNX1-2.
FT   REGION     1913   1948       Required for activation of RUNX1-2.
FT   COMPBIAS    371    379       Poly-Ser.
FT   COMPBIAS    788    801       Poly-Glu.
FT   COMPBIAS    989    995       Poly-Glu.
FT   COMPBIAS   1019   1026       Poly-Arg.
FT   COMPBIAS   1069   1078       Poly-Glu.
FT   COMPBIAS   1147   1150       Poly-Lys.
FT   COMPBIAS   1221   1242       Glu-rich.
FT   COMPBIAS   1267   1302       Glu-rich.
FT   COMPBIAS   1411   1414       Poly-Glu.
FT   COMPBIAS   1593   1597       Poly-Ser.
FT   COMPBIAS   1643   1704       Gln/Pro-rich.
FT   COMPBIAS   1897   1977       Met-rich.
FT   ACT_SITE    680    680       Proton donor/acceptor.
FT                                {ECO:0000250|UniProtKB:Q9H7Z6}.
FT   BINDING     684    684       Acetyl-CoA. {ECO:0000269|Ref.26}.
FT   SITE        813    814       Breakpoint for translocation to form
FT                                KAT6A-ASXL2.
FT   SITE       1117   1118       Breakpoint for translocation to form
FT                                KAT6A-EP300 and KAT6A-NCOA2.
FT   SITE       1546   1547       Breakpoint for translocation to form
FT                                KAT6A-CREBBP.
FT   MOD_RES     172    172       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BZ21}.
FT   MOD_RES     350    350       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     355    355       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     369    369       Phosphothreonine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:23431171}.
FT   MOD_RES     420    420       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     473    473       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     604    604       N6-acetyllysine; by autocatalysis.
FT                                {ECO:0000269|Ref.26}.
FT   MOD_RES     787    787       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BZ21}.
FT   MOD_RES     812    812       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     815    815       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BZ21}.
FT   MOD_RES     899    899       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q5TKR9}.
FT   MOD_RES     941    941       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     954    954       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     974    974       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1007   1007       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1089   1089       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1090   1090       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1113   1113       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   VARIANT     134    134       L -> S (in dbSNP:rs3824276).
FT                                /FTId=VAR_047548.
FT   MUTAGEN     543    543       C->G: Abrogates HAT activity.
FT                                {ECO:0000269|PubMed:12676584}.
FT   MUTAGEN     545    545       K->A: Reduced affinity for DNA.
FT                                {ECO:0000269|PubMed:17925393}.
FT   MUTAGEN     657    657       G->E: Abrogates HAT activity.
FT                                {ECO:0000269|PubMed:12676584}.
FT   MUTAGEN     727    727       I->E: Slightly reduced affinity for DNA.
FT                                {ECO:0000269|PubMed:17925393}.
FT   MUTAGEN     732    732       H->D: Reduced affinity for DNA.
FT                                {ECO:0000269|PubMed:17925393}.
FT   CONFLICT    401    401       K -> R (in Ref. 1; AAC50662 and 3;
FT                                BAD00088). {ECO:0000305}.
FT   HELIX       195    197       {ECO:0000244|PDB:5B78}.
FT   STRAND      198    200       {ECO:0000244|PDB:5B76}.
FT   STRAND      207    209       {ECO:0000244|PDB:5B78}.
FT   TURN        210    212       {ECO:0000244|PDB:5B78}.
FT   TURN        231    233       {ECO:0000244|PDB:5B78}.
FT   HELIX       239    242       {ECO:0000244|PDB:5B78}.
FT   HELIX       246    252       {ECO:0000244|PDB:5B78}.
FT   TURN        253    256       {ECO:0000244|PDB:5B78}.
FT   TURN        260    262       {ECO:0000244|PDB:5B78}.
FT   TURN        266    268       {ECO:0000244|PDB:5B78}.
FT   HELIX       275    277       {ECO:0000244|PDB:5B78}.
FT   STRAND      278    280       {ECO:0000244|PDB:4LK9}.
FT   TURN        282    284       {ECO:0000244|PDB:5B78}.
FT   STRAND      287    289       {ECO:0000244|PDB:4LK9}.
FT   HELIX       290    292       {ECO:0000244|PDB:5B78}.
FT   STRAND      293    295       {ECO:0000244|PDB:5B78}.
FT   TURN        308    310       {ECO:0000244|PDB:5B78}.
FT   STRAND      511    514       {ECO:0000244|PDB:2OZU}.
FT   STRAND      517    520       {ECO:0000244|PDB:2OZU}.
FT   HELIX       529    532       {ECO:0000244|PDB:2RC4}.
FT   STRAND      535    539       {ECO:0000244|PDB:2OZU}.
FT   TURN        541    543       {ECO:0000244|PDB:2OZU}.
FT   STRAND      546    549       {ECO:0000244|PDB:2OZU}.
FT   HELIX       550    559       {ECO:0000244|PDB:2OZU}.
FT   STRAND      566    573       {ECO:0000244|PDB:2OZU}.
FT   STRAND      576    582       {ECO:0000244|PDB:2OZU}.
FT   TURN        583    585       {ECO:0000244|PDB:2OZU}.
FT   HELIX       587    598       {ECO:0000244|PDB:2OZU}.
FT   STRAND      613    622       {ECO:0000244|PDB:2OZU}.
FT   STRAND      625    637       {ECO:0000244|PDB:2OZU}.
FT   STRAND      642    649       {ECO:0000244|PDB:2OZU}.
FT   HELIX       651    653       {ECO:0000244|PDB:2OZU}.
FT   STRAND      655    657       {ECO:0000244|PDB:2RC4}.
FT   HELIX       658    672       {ECO:0000244|PDB:2OZU}.
FT   STRAND      677    679       {ECO:0000244|PDB:2OZU}.
FT   HELIX       685    705       {ECO:0000244|PDB:2OZU}.
FT   HELIX       713    720       {ECO:0000244|PDB:2OZU}.
FT   HELIX       724    733       {ECO:0000244|PDB:2OZU}.
FT   HELIX       750    759       {ECO:0000244|PDB:2OZU}.
FT   HELIX       771    773       {ECO:0000244|PDB:2OZU}.
SQ   SEQUENCE   2004 AA;  225028 MW;  78357EFAC4698A5F CRC64;
     MVKLANPLYT EWILEAIKKV KKQKQRPSEE RICNAVSSSH GLDRKTVLEQ LELSVKDGTI
     LKVSNKGLNS YKDPDNPGRI ALPKPRNHGK LDNKQNVDWN KLIKRAVEGL AESGGSTLKS
     IERFLKGQKD VSALFGGSAA SGFHQQLRLA IKRAIGHGRL LKDGPLYRLN TKATNVDGKE
     SCESLSCLPP VSLLPHEKDK PVAEPIPICS FCLGTKEQNR EKKPEELISC ADCGNSGHPS
     CLKFSPELTV RVKALRWQCI ECKTCSSCRD QGKNADNMLF CDSCDRGFHM ECCDPPLTRM
     PKGMWICQIC RPRKKGRKLL QKKAAQIKRR YTNPIGRPKN RLKKQNTVSK GPFSKVRTGP
     GRGRKRKITL SSQSASSSSE EGYLERIDGL DFCRDSNVSL KFNKKTKGLI DGLTKFFTPS
     PDGRKARGEV VDYSEQYRIR KRGNRKSSTS DWPTDNQDGW DGKQENEERL FGSQEIMTEK
     DMELFRDIQE QALQKVGVTG PPDPQVRCPS VIEFGKYEIH TWYSSPYPQE YSRLPKLYLC
     EFCLKYMKSR TILQQHMKKC GWFHPPANEI YRKNNISVFE VDGNVSTIYC QNLCLLAKLF
     LDHKTLYYDV EPFLFYVLTQ NDVKGCHLVG YFSKEKHCQQ KYNVSCIMIL PQYQRKGYGR
     FLIDFSYLLS KREGQAGSPE KPLSDLGRLS YMAYWKSVIL ECLYHQNDKQ ISIKKLSKLT
     GICPQDITST LHHLRMLDFR SDQFVIIRRE KLIQDHMAKL QLNLRPVDVD PECLRWTPVI
     VSNSVVSEEE EEEAEEGENE EPQCQERELE ISVGKSVSHE NKEQDSYSVE SEKKPEVMAP
     VSSTRLSKQV LPHDSLPANS QPSRRGRWGR KNRKTQERFG DKDSKLLLEE TSSAPQEQYG
     ECGEKSEATQ EQYTESEEQL VASEEQPSQD GKPDLPKRRL SEGVEPWRGQ LKKSPEALKC
     RLTEGSERLP RRYSEGDRAV LRGFSESSEE EEEPESPRSS SPPILTKPTL KRKKPFLHRR
     RRVRKRKHHN SSVVTETISE TTEVLDEPFE DSDSERPMPR LEPTFEIDEE EEEEDENELF
     PREYFRRLSS QDVLRCQSSS KRKSKDEEED EESDDADDTP ILKPVSLLRK RDVKNSPLEP
     DTSTPLKKKK GWPKGKSRKP IHWKKRPGRK PGFKLSREIM PVSTQACVIE PIVSIPKAGR
     KPKIQESEET VEPKEDMPLP EERKEEEEMQ AEAEEAEEGE EEDAASSEVP AASPADSSNS
     PETETKEPEV EEEEEKPRVS EEQRQSEEEQ QELEEPEPEE EEDAAAETAQ NDDHDADDED
     DGHLESTKKK ELEEQPTRED VKEEPGVQES FLDANMQKSR EKIKDKEETE LDSEEEQPSH
     DTSVVSEQMA GSEDDHEEDS HTKEELIELK EEEEIPHSEL DLETVQAVQS LTQEESSEHE
     GAYQDCEETL AACQTLQSYT QADEDPQMSM VEDCHASEHN SPISSVQSHP SQSVRSVSSP
     NVPALESGYT QISPEQGSLS APSMQNMETS PMMDVPSVSD HSQQVVDSGF SDLGSIESTT
     ENYENPSSYD STMGGSICGN SSSQSSCSYG GLSSSSSLTQ SSCVVTQQMA SMGSSCSMMQ
     QSSVQPAANC SIKSPQSCVV ERPPSNQQQQ PPPPPPQQPQ PPPPQPQPAP QPPPPQQQPQ
     QQPQPQPQQP PPPPPPQQQP PLSQCSMNNS FTPAPMIMEI PESGSTGNIS IYERIPGDFG
     AGSYSQPSAT FSLAKLQQLT NTIMDPHAMP YSHSPAVTSY ATSVSLSNTG LAQLAPSHPL
     AGTPQAQATM TPPPNLASTT MNLTSPLLQC NMSATNIGIP HTQRLQGQMP VKGHISIRSK
     SAPLPSAAAH QQQLYGRSPS AVAMQAGPRA LAVQRGMNMG VNLMPTPAYN VNSMNMNTLN
     AMNSYRMTQP MMNSSYHSNP AYMNQTAQYP MQMQMGMMGS QAYTQQPMQP NPHGNMMYTG
     PSHHSYMNAA GVPKQSLNGP YMRR
//
